Expression of signaling proteins (p-ERF, Grb-2, MAPK, and p-MAPK) in tumour tissuefrom letrozole-treated mice at weeks 4, 28, and 56 compared to control tumours at 4 weeks. Proteinextracts from tumour tissues were prepared by homogenizing the tissue and cells in lysis buffer.Proteins in the lysates were separated on a denaturing polyacrylamide gel and transferred to a nitrocellulose membrane. The protein-bound membranes were then incubated for 1 h at room temperaturewith 0.1% Tween 20 in PBS (PBS-T) and 5% non-fat dried milk to block non-specific binding to antibodies. The membranes were then incubated with respective primary antibodies in PBS-T milk for1 h, and specific binding was visualized by using species-specific IgGs followed by enhanced chemiluminescence detection (ECL kit; Amersham Biosciences) and exposure to ECL X-ray film.UMB-1CAcells compared to MCF-7CAcells . Consistent withthese results, best price for generic viagra proliferation of UMB-1CAcould be inhibited by wortmanninand phosphoinositide 3-kinase inhibitors but not by MAPK inhibitors(PD98059) . No increase in the Akt pathway was seen in the LTLT cells.This suggests that depriving the cells of oestrogen by aromatase inhibitionresults in activation of a different pathway from that of cells deprived ofoestrogen in the medium. The activation of the Akt pathway in UMB-1CAcellsappears to be similar to observations reported for MCF-7 cells deprived ofoestrogen in culture and involves crosstalk between the ER and Akt signaling . UMB-1CAcells were susceptible to growth inhibition by theoestrogen downregulator Faslodex, whereas no such inhibition was apparent inthe LTLT cells, consistent with results in the tumour model. Thus, activationof the Raf-MAPK pathway in LTLT cells may represent a more extreme formof oestrogen deprivation that could occur with long-term letrozole treatment.In the LTLT cells, proliferation was inhibited by the MAPK inhibitor PD98059and the MEK1/2 inhibitor U0126 (obtained from best price for generic viagra Signaling). These compounds were without effects on MCF-7CAproliferation. Iressa, an inhibitor ofepidermal growth factor (EGF) tyrosine kinase, was effective in both UMB-1CAand LTLT cells, suggesting the involvement of EGF in the activation ofthis pathway .Figure 6. The effect of letrozole and fulvestant alone or in the combination on the growth of MCF-7CAbreast tumour xenografts in female, ovariectomized, athymic, nude mice. All mice receivedandrostenedione (100 μg/day sc). When tumours reached approximately 300 mm3animals were divided into four groups and injected subcutaneously daily with vehicle (control; n = 6), fulvestrant(1 mg/day; n = 7), letrozole (10 μg/day; n = 18), or letrozole (10 μg/day) plus fulvestrant (1 mg/day;n = 5). Tumour volumes were measured weekly and expressed as the percentage change in meantumour volume relative to the initial size at week 0. At week 7, all treatments were significantly better at suppressing tumour growth compared to the control (P < 0.0001); all control animals were killeddue to large tumour size. At week 17, letrozole was superior to fulvestrant in controlling tumourgrowth (P < 0.001). Also, treatment with letrozole plus fulvestrant was superior to fulvestrant alone(P < 0.001). Fulvestrant-treated mice were killed at week 17 due to large tumour size. At week 29,letrozole (10 μg/day) was less effective than letrozole plus fulvestrant in controlling tumour growth(P = 0.0005). Also, at week 29, tumour volume were statistically significantly larger in the letrozoletreatment group, than in the combination (P < 0.0001).This implies that some transcription via the ER may occur with fulvestrant treatment alone that is notcompletely blocked by the antioestrogen. The combined treatment resulted intumour regression, which was maintained throughout the 29-week treatmentperiod . This result indicates that the combination of reducing oestrogenproduction and downregulating the ER could prevent or delay development ofresistance to letrozole. Expression of erbB2 and MAPK were increased, relative to control samples, in tumours treated with letrozole and fulvestrant.However, there was no increase observed in tumours of mice treated with thecombination . These findings suggest that the combination of fulvestrantwith letrozole could be more effective in breast cancer patients than theseagents administered separately.In conclusion, a number of animal models have been utilized for preclinicalstudies of aromatase inhibitors. Some models are valuable for assessing theinhibition of oestrogen production from the ovary and also peripheral aromatization as well as on feedback regulation and other hormonal effects. Othermodels are relevant to anti-tumour activity. In the carcinogen-induced(DMBA/NMU) tumour models, the source of oestrogen is the ovary and,therefore, is under gonadotrophin feedback control. The advantages of thexenograft model are that tumours of human breast cancer cells are used andalso that oestrogen is produced by aromatization from a non-ovarian source.These models come close to representing aspects of the situation in patients.However, there are no human breast cancer best price for generic viagra lines available at present inwhich growth is dependent on oestrogen and which express both ER and aromatase. Nevertheless, cells that are produced as a result of exposure to aromatase inhibitors are proving useful in culture and also as xenografts.